Malin Corporation (MLC) Fair Value & Analysis
Healthcare · IE · Market cap €31.6M
Fair value as of: Jul 17, 2026
From 1 valuation models · updated today
Fair value updated Jul 17, 2026, revised from €200.96 to €13.24 (−93.4%) since Jun 24, 2026. Share price −2.0% over the past month.
Price vs Fair Value (12 months)
12‑month range €7.00 – €8.65 · fair‑value band €8.74 – €16.56 · the €7.30 price screens below the €13.24 fair value. As of Jul 17, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Malin Corporation (MLC) currently trades at €7.30, while our model-based Fair Value estimate is €13.24, implying the stock looks roughly 81.4% undervalued today. We read business quality at 60/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low), always confirm before acting.
Trailing-twelve-month revenue stands at €41.0M. Revenue grew 23.1% year over year. It earns a return on equity of -6.0%. The balance sheet holds a net cash position of €32.6M. Fundamentals as of Jul 17, 2026
Our scenario range runs from €8.74 (bear case) to €16.56 (bull case); at €7.30, the current price sits below that range. The share trades about 22% below its 52-week high and 4% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -37% fair-value upside, at 81%, MLC screens cheaper than that median.
Key figures & financial health
Figures from reported company fundamentals (EODHD) · as of Jul 17, 2026. TTM = trailing twelve months.
About the company
Malin Corporation plc, together with its subsidiaries, operates as an investment company in Europe and North America. It engages in the investment in life sciences and healthcare companies targeting various therapeutic areas, including oncology, immunology, and genetic diseases. The company was incorporated in 2014 and is headquartered in Dublin, Ireland.
Revenue & earnings trend
FY2020 – FY2024 · reported fiscal years
Malin Corporation reported revenue of €0 in FY2024 versus €41.0M in FY2020. Reported net income was €0 in FY2024.
Is MLC fairly valued? → Check now
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 17, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,786 | ₹991.46 | -44% |
| Hansoh Pharmaceutical Group 3692 | HK$29.58 | HK$18.75 | -37% |
| Divi's Laboratories Limited DIVISLAB | ₹6,639 | ₹1,281 | -81% |
| PharmaEssentia Corporation 6446 | 937.00 TWD | 322.35 TWD | -66% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,421 | ₹1,504 | -66% |
| Cipla Limited CIPLA | ₹1,433 | ₹1,035 | -28% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,089 | ₹841.98 | -23% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,291 | ₹1,053 | -18% |
| Lupin Limited LUPIN | ₹2,268 | ₹2,697 | +19% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Malin Corporation (MLC) undervalued?
What is the fair value of MLC?
What is the quality score of MLC?
What is the revenue of Malin Corporation (MLC)?
What is the net profit margin of MLC?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Tell me when Malin Corporation reaches its Fair Value
Just your email, and we'll notify you when the price and Fair Value of Malin Corporation materially change. Free bonus: the monthly Top-25 report of the most undervalued quality stocks.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.